SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Merck Says KEYTRUDA Reduced Progression or Death Risk by 43% in Endometrial Cancer Trial

Merck said first results from its Phase 3 KEYNOTE-C93 trial found KEYTRUDA monotherapy reduced the risk of disease progression or death by 43% versus chemotherapy in certain patients with advanced or recurrent endometrial cancer and dMMR tumors.

MRK

Story updates

03:35:28 PM UTC
SquawkNews
KEYNOTE-C93 showed median progression-free survival (PFS) was more than four times longer for these

Related stories